Structured Docosahexaenoic Acid (DHA) Enhances Motility and Promotes the Antioxidant Capacity of Aged C. elegans.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Mora I
- Pérez-Santamaria A
- Arola L
- Puiggròs F
Grupos
Abstract
The human lifespan has increased over the past century; however, healthspans have not kept up with this trend, especially cognitive health. Among nutrients for brain function maintenance, long-chain omega-3 polyunsaturated fatty acids (?-3 LCPUFA): DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) must be highlighted, particularly structured forms of EPA and DHA which were developed to improve bioavailability and bioactivity in comparison with conventional ?-3 supplements. This study aims to elucidate the effect of a structured triglyceride form of DHA (DHA-TG) on the healthspan of aged C. elegans. Using a thrashing assay, the nematodes were monitored at 4, 8, and 12 days of adulthood, and DHA-TG improved its motility at every age without affecting lifespan. In addition, the treatment promoted antioxidant capacity by enhancing the activity and expression of SOD (superoxide dismutase) in the nematodes. Lastly, as the effect of DHA-TG was lost in the DAF-16 mutant strain, it might be hypothesized that the effects of DHA need DAF-16/FOXO as an intermediary. In brief, DHA-TG exerted a healthspan-promoting effect resulting in both enhanced physical fitness and increased antioxidant defense in aged C. elegans. For the first time, an improvement in locomotive function in aged wild-type nematodes is described following DHA-TG treatment.
Datos de la publicación
- ISSN/ISSNe:
- 2073-4409, 2073-4409
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37566010
- Factor de Impacto:
- 1,452 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Cells MDPI
Documentos
- No hay documentos
Filiaciones
Keywords
- C. elegans; DAF-16/FOXO; PUFA; aging; antioxidant; cognitive decline; docosahexaenoic acid; healthspan; nematode; omega-3; oxidative stress; physical decline; structured lipids
Proyectos y Estudios Clínicos
MOLECULAR MECHANISMS OF PROTEIN AGGREGATION IN VITRO AND IN VIVO MODELS OF HUNTINGTON DISEASE
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
CP11/00090 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012
MECHAGGRENAMICS. MECHANISMS OF CELL DYSFUNCTION BY AGGREGATION DYNAMICS OF POLYQ-CONTAINING PROTEINS
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
322034_MARIE_CURIE_VAZQUEZ_FP7-PEOPLE-2012-CIG . COMISION EUROPEA; ASOCIACION VALENCIANA DE ENFERMEDAD HUNTINGTON . 2012
COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
ESTRATEGIAS TERAPÉUTICAS CONTRA LA TOXICIDAD PRODUCIDA POR PÉPTIDOS Y RNA CODIFICADOS POR EL ALELO MUTANTE DE HTT EN LA ENFERMEDAD DE HUNTINGTON.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PI14/00949 . INSTITUTO DE SALUD CARLOS III . 2015
MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017
Mecanismos y estrategias terapéuticas en la Enfermedad de Huntington mediante metformina y salicilato.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PI17/00011 . INSTITUTO DE SALUD CARLOS III . 2018
Estrategia terapéutica contra la enfermedad de Huntington mediante la activación sinergística de AMPK.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
2018_0381_CRC_RAMON ARECES_VAZQUEZ . FUNDACIÓN RAMÓN ARECES . 2019
Tu hospital investiga RRI.
Investigador Principal: ANA ISABEL JUAN ROCH
FCT-18-14018 . FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA . 2019
Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive decline in patients with Huntington's disease. TEMET-HD
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
ICI19/00014 . INSTITUTO DE SALUD CARLOS III . 2020
Activación sinérgica de AMPK para detener el progreso de la enfermedad de Huntington
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
ACIF/2020/366 . CONSELLERIA DE EDUCACION . 2020
Modulating the activity of genes controlling fat metabolism as a therapeutic strategy in Huntington disease.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PI20/00114 . INSTITUTO DE SALUD CARLOS III . 2021
Plataforma ISCIII de Biobancos y Biomodelos
Investigador Principal: JOSÉ VICENTE CERVERA ZAMORA
PT20/00179 . INSTITUTO DE SALUD CARLOS III . 2021
ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA EVALUAR EL EFECTO DE LA METFORMINA, UN ACTIVADOR DE LA AMPK, SOBRE MEDIDAS COGNITIVAS DE PROGRESIÓN EN PACIENTES DE LA ENFERMEDAD DE HUNTINGTON.
Investigador Principal: CARMEN PEIRÓ VILAPLANA
TEMET-HD . 2020
MODFAT-HD-Modulators of fat metabolism as druggable targets to treat Huntington Disease.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PCI2021-122099-2B . COMISION EUROPEA . 2022
Uso de ubiquibodies in vitro para el tratamiento de distrofias hereditarias de la retina dominantes asociadas a mutaciones en CRX.
Investigador Principal: JOSÉ MARÍA MILLÁN SALVADOR
2022-852-1_CRC_ONCE_MILLAN . ONCE . 2022
Cita
Mora I,Pérez A,TORTAJADA J,VÁZQUEZ RP,Arola L,Puiggròs F. Structured Docosahexaenoic Acid (DHA) Enhances Motility and Promotes the Antioxidant Capacity of Aged C. elegans. Cells. 2023. 12. (15):1932. IF:5,100. (2).